与整合酶抑制剂相关的抗病毒治疗研究新进展

Research Progress in Antiviral Treatment Regimens Associated with Integrase Inhibitors

2018年底,我国发布的最新的抗病毒治疗指南中纳入了整合酶抑制剂(INIs),一种更高效的抗病毒治疗药物。非核苷类逆转录酶抑制剂的高耐药率是当前将INIs纳入治疗方案的关键考虑因素。国外关于INIs的研究有不少报道,尽管与现有的一线治疗方案相比,基于INIs的治疗方案具有更好的疗效和耐受性,然而,仍然有临床数据显示几类INIs的安全性不够及轻微耐药的情况。目前,国内关于INIs的用药指导仍参考国外,因此,为了获得高效的治疗方案,实时掌握国际研究动态至关重要。

At the end of 2018,China’s latest antiviral treatment guidelines included integrase inhibitors(INIs),a more effective antiviral treatment.The high resistance rate of non-nucleoside reverse transcriptase inhibitors is currently a key consideration in the inclusion of INIs into the treatment regimens.There have been many reports on INIs abroad,although INIs-based treatments have better efficacy and tolerability than existing first-line treatments,there are still clinical data on the safety and mild resistance of several types of INIs.At present,domestic drug guidance for INIs is still from foreign references.Therefore,it is important to grasp the international research dynamics in real time in order to obtain an effective treatment plan.